Role of microbiome in cancer immunotherapy

No abstract is available for this paper.

• Publication year

  2022

• Venue

  Unknown venue

• Publication date

  Unknown publication date

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1016/B978-0-12-823397-9.00010-7
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• The Link "Cancer and autoimmune diseases" in the light of microbiota: evidence of a potential culprit.

  2020cited by this paper
• Exploring the food-gut axis in immunotherapy response of cancer patients

  2020cited by this paper
• Microbiome-derived inosine modulates response to checkpoint inhibitor immunotherapy

  2020cited by this paper
• A part‐dependent account of biological individuality: why holobionts are individuals and ecosystems simultaneously

  2020cited by this paper
• Constructing and Characterizing Bacteriophage Libraries for Phage Therapy of Human Infections

  2019cited by this paper
• A defined commensal consortium elicits CD8 T cells and anti-cancer immunity

  2019cited by this paper
• The microbiome, cancer, and cancer therapy

  2019cited by this paper
• The Diversity of Gut Microbiome is Associated With Favorable Responses to Anti-Programmed Death 1 Immunotherapy in Chinese Patients With NSCLC.

  2019cited by this paper
• Editing the microbiome the CRISPR way

  2019cited by this paper
• FETR-ALS Study Protocol: A Randomized Clinical Trial of Fecal Microbiota Transplantation in Amyotrophic Lateral Sclerosis

  2019cited by this paper
• Gut microbiome and CAR-T therapy

  2019cited by this paper
• Differential Responses of Colorectal Cancer Cell Lines to Enterococcus faecalis’ Strains Isolated from Healthy Donors and Colorectal Cancer Patients

  2019cited by this paper
• The Immune Landscape of Cancer.

  2018cited by this paper
• Treatment of acute lymphoblastic leukaemia with the second generation of CD19 CAR‐T containing either CD28 or 4‐1BB

  2018cited by this paper
• The Influence of the Gut Microbiome on Cancer, Immunity, and Cancer Immunotherapy.

  2018cited by this paper
• The commensal microbiome is associated with anti–PD-1 efficacy in metastatic melanoma patients

  2018cited by this paper
• Chimeric Antigen Receptor Therapy.

  2018cited by this paper
• The revving up of CARs

  2018cited by this paper
• Why does the microbiome affect behaviour?

  2018cited by this paper
• Gut microbiome influences efficacy of PD-1–based immunotherapy against epithelial tumors

  2018cited by this paper
• Gut microbiome modulates response to anti–PD-1 immunotherapy in melanoma patients

  2018cited by this paper
• Scientists on the Spot: Salt, the microbiome, and cardiovascular diseases

  2018cited by this paper
• Microbial modulation of the gut microbiome for treating autoimmune diseases

  2018cited by this paper
• I’ve Gut A Feeling: Microbiota Impacting the Conceptual and Experimental Perspectives of Personalized Medicine

  2018cited by this paper
• Role of diet and gut microbiota on colorectal cancer immunomodulation

  2018cited by this paper
• The Past and Future Biology of the Human Microbiome in an Age of Extinctions.

  2018cited by this paper
• Synthetic Biology Approaches to Engineer Probiotics and Members of the Human Microbiota for Biomedical Applications.

  2018cited by this paper
• Bringing the Next Generation of Immuno-Oncology Biomarkers to the Clinic

  2018cited by this paper
• Fecal microbiota transplantation associated with 10 years of stability in a patient with SPMS

  2018cited by this paper
• The Different Functional Distribution of “Not Effector” T Cells (Treg/Tnull) in Colorectal Cancer

  2017cited by this paper
• Cancer immunotherapy: Opportunities and challenges in the rapidly evolving clinical landscape.

  2017cited by this paper
• The interplay between host immune cells and gut microbiota in chronic inflammatory diseases

  2017cited by this paper
• Baseline gut microbiota predicts clinical response and colitis in metastatic melanoma patients treated with ipilimumab

  2017cited by this paper
• Homeostatic Immunity and the Microbiota.

  2017cited by this paper
• Metagenomic Shotgun Sequencing and Unbiased Metabolomic Profiling Identify Specific Human Gut Microbiota and Metabolites Associated with Immune Checkpoint Therapy Efficacy in Melanoma Patients

  2017cited by this paper
• Anticancer effects of the microbiome and its products

  2017cited by this paper
• Chimeric antigen receptor T cells: a novel therapy for solid tumors

  2017cited by this paper
• Axicabtagene Ciloleucel CAR T‐Cell Therapy in Refractory Large B‐Cell Lymphoma

  2017cited by this paper
• Intra-tumor heterogeneity from a cancer stem cell perspective

  2017cited by this paper
• Cancer Immunotherapy: Historical Perspective of a Clinical Revolution and Emerging Preclinical Animal Models

  2017cited by this paper
• Clinical trials of CAR-T cells in China

  2017cited by this paper
• Engineering Diagnostic and Therapeutic Gut Bacteria

  2017cited by this paper
• Clonal Heterogeneity and Tumor Evolution: Past, Present, and the Future.

  2017cited by this paper
• Potential role of intratumor bacteria in mediating tumor resistance to the chemotherapeutic drug gemcitabine

  2017cited by this paper
• The future of cancer treatment: immunomodulation, CARs and combination immunotherapy

  2016cited by this paper
• The interplay between the microbiome and the adaptive immune response in cancer development

  2016cited by this paper
• Revised Estimates for the Number of Human and Bacteria Cells in the Body

  2016cited by this paper
• Accounting for reciprocal host–microbiome interactions in experimental science

  2016cited by this paper
• Peripheral ENO1-specific T cells mirror the intratumoral immune response and their presence is a potential prognostic factor for pancreatic adenocarcinoma.

  2016cited by this paper
• Signals from the gut microbiota to distant organs in physiology and disease

  2016cited by this paper
• How to Manipulate the Microbiota: Fecal Microbiota Transplantation.

  2016cited by this paper
• Current Challenges in Cancer Treatment.

  2016cited by this paper
• Economic sustainability of anti-PD-1 agents nivolumab and pembrolizumab in cancer patients: Recent insights and future challenges.

  2016cited by this paper
• Alterations of the human gut microbiome in multiple sclerosis

  2016cited by this paper
• Fine-Tuning Cancer Immunotherapy: Optimizing the Gut Microbiome.

  2016cited by this paper
• Intra-tumoral IFN-γ-producing Th22 cells correlate with TNM staging and the worst outcomes in pancreatic cancer.

  2016cited by this paper
• The development of immunotherapy in older adults: New treatments, new toxicities?

  2016cited by this paper
• Commensal Bifidobacterium promotes antitumor immunity and facilitates anti–PD-L1 efficacy

  2015cited by this paper
• Dysbiotic infection in the stomach.

  2015cited by this paper
• Cancer immunotherapy: harnessing the immune system to battle cancer.

  2015cited by this paper
• Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer.

  2015cited by this paper
• Immunotherapy Approaches in Cancer Treatment.

  2015cited by this paper
• The future of immune checkpoint therapy

  2015cited by this paper
• Host Biology in Light of the Microbiome: Ten Principles of Holobionts and Hologenomes

  2015cited by this paper
• Cancer and the Immune System: Basic Concepts and Targets for Intervention.

  2015cited by this paper
• New approaches for cancer immunotherapy

  2015cited by this paper
• Cancer immunology for the clinician.

  2015cited by this paper
• Whole-ecosystem experimental manipulations of tropical forests.

  2015cited by this paper
• Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota

  2015cited by this paper
• Eco-Evo-Devo: developmental symbiosis and developmental plasticity as evolutionary agents

  2015cited by this paper
• Role of the microbiota in immunity and inflammation.

  2014cited by this paper
• The effects of intestinal tract bacterial diversity on mortality following allogeneic hematopoietic stem cell transplantation.

  2014cited by this paper
• Helicobacter pylori secreted peptidyl prolyl cis, trans-isomerase drives Th17 inflammation in gastric adenocarcinoma

  2014cited by this paper
• Cancer immunotherapies, their safety and toxicity

  2013cited by this paper
• Compartmentalized and systemic control of tissue immunity by commensals

  2013cited by this paper
• Ex vivo analysis of pancreatic cancer-infiltrating T lymphocytes reveals that ENO-specific Tregs accumulate in tumor tissue and inhibit Th1/Th17 effector cell functions

  2013cited by this paper
• Chimeric antigen receptor-modified T cells for acute lymphoid leukemia.

  2013cited by this paper
• Innate and adaptive immune cells in the tumor microenvironment

  2013cited by this paper
• IL-22 is related to development of human colon cancer by activation of STAT3

  2013cited by this paper
• Innate lymphoid cells sustain colon cancer through production of interleukin-22 in a mouse model

  2013cited by this paper
• Role of the intestinal microbiome in health and disease: from correlation to causation.

  2012cited by this paper
• 4-hydroxy-2-nonenal mediates genotoxicity and bystander effects caused by Enterococcus faecalis-infected macrophages.

  2012cited by this paper
• Structure, Function and Diversity of the Healthy Human Microbiome

  2012cited by this paper
• A bacterial driver–passenger model for colorectal cancer: beyond the usual suspects

  2012cited by this paper
• Interleukin 23 production by intestinal CD103(+)CD11b(+) dendritic cells in response to bacterial flagellin enhances mucosal innate immune defense.

  2012cited by this paper
• Techniques used to characterize the gut microbiota: a guide for the clinician

  2012cited by this paper
• The ultimate social network.

  2012cited by this paper
• Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.

  2012cited by this paper
• Microbiota-induced IL-1β, but not IL-6, is critical for the development of steady-state TH17 cells in the intestine

  2012cited by this paper
• Adenoma-linked barrier defects and microbial products drive IL-23/IL-17-mediated tumour growth

  2012cited by this paper
• Host-Gut Microbiota Metabolic Interactions

  2012cited by this paper
• The keystone-pathogen hypothesis

  2012cited by this paper
• Promotion of hepatocellular carcinoma by the intestinal microbiota and TLR4.

  2012cited by this paper
• Structure of the human gastric bacterial community in relation to Helicobacter pylori status

  2011cited by this paper
• Perspective: alpha-bugs, their microbial partners, and the link to colon cancer.

  2011cited by this paper
• Th17 cells in cancer: help or hindrance?

  2011cited by this paper
• Human nutrition, the gut microbiome and the immune system

  2011cited by this paper
• Ipilimumab plus dacarbazine for previously untreated metastatic melanoma.

  2011cited by this paper
• Cancer Immunoediting: Integrating Immunity’s Roles in Cancer Suppression and Promotion

  2011cited by this paper
• A new vision of immunity: homeostasis of the superorganism

  2010cited by this paper

• Editorial: The mechanism of immune cells in the development of inflammatory bowel disease (IBD) and colitis-associated colorectal cancer (CAC)

  2023cites this paper